We are 209,651 members in 82 forums discussing 150,638 topics.

Help with Abbreviations

All TopicsForum: Clinical Trials, Research News, Podcasts, Study Results → Topic: Breaking Research News from sources other than breastcancer.org

Topic: Breaking Research News from sources other than breastcancer.org

Forum: Clinical Trials, Research News, Podcasts, Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Nov 21, 2017 05:31AM - edited Nov 21, 2017 05:35AM by Lumpie

Lumpie wrote:

I watch for research news on breast cancer, treatments, etc., and frequently see interesting articles. There is a topic on BCO called "Breaking Research News from Breastcancer.org." One of the moderators suggested that another topic might be appropriate for posting links and synopses of reports on research found elsewhere. So here it is! Please post links to reports on research form reliable sources. Thanks for sharing!

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Page 16 of 16 (479 results)

Posts 451 - 479 (479 total)

Log in to post a reply

Aug 3, 2018 04:34PM Lumpie wrote:

CXCR4 Antagonists and Breast Cancer

https://www.practiceupdate.com/c/69235/67/13/?elsc...

{video/interview} Timothy J Pluard MD

"...we saw a significant response rate of about 36% in these heavily pretreated patients and about 60+% clinical benefit in these patients. So, there's a signal there that's obviously a phase I trial with early data, but I think it gives us the groundwork to move forward with additional studies. The FDA has granted fast track designation, so we're moving forward with additional studies."

{poster note: This sounds very promising!}

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 4, 2018 01:03AM Lumpie wrote:

Increased Out-of-Pocket Expenditures Among Women With Metastatic Breast Cancer in High-Deductible Health Plans

https://www.practiceupdate.com/c/69776/67/13/?elsc...

  • In this longitudinal study, data of 5364 women with metastatic breast cancer who were insured by a large US insurer from 2004 to 2011 were evaluated to determine trends in total and out-of-pocket costs. The percentage of women enrolled in high-deductible health plans increased from 8% to 23%, whereas the percentage enrolled in low-deductible health plans decreased from 69% to 37%. Overall, the estimated annual inflation-adjusted health service spending increased $1197 per year; annual out-of-pocket spending did not change. Women in high-deductible health plans reported 55% more out-of-pocket spending compared with women in low-deductible health plans.
  • These findings highlight the need for new health plans that protect patients with metastatic breast cancer from high out-of-pocket costs.

Published in Metastatic Breast Cancer July 25, 2018

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 4, 2018 04:12AM Lumpie wrote:

Surgeon Attitudes Toward the Omission of Axillary Dissection in Early Breast Cancer

https://www.practiceupdate.com/C/70820/56?elsca1=e...

  • In this survey of 376 surgeons, 49% would definitely or probably recommend axillary dissection for one sentinel node macrometastasis and 63% would definitely or probably recommend axillary dissection for two sentinel node macrometastases. In multivariable analysis, a lower propensity for axillary dissection was significantly associated with treatment of more breast cancer cases, acceptance of a lumpectomy margin of no ink on tumor, multidisciplinary tumor board participation, and Los Angeles SEER site.
  • The potential for overtreatment identified in this study indicates the need for education targeted toward lower-volume breast surgeons.
jamanetwork.com/journals/jamao...
"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 4, 2018 04:19AM Lumpie wrote:

Women with higher vitamin D blood levels have lower risk for breast cancer

https://www.news-medical.net/news/20180618/Women-w...

Results from a new study published in PLOS ONE shows women who have higher vitamin D blood levels have a significantly lower risk for breast cancer.

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 4, 2018 04:20AM - edited Aug 4, 2018 04:37AM by Lumpie

Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer

https://www.news-medical.net/news/20180711/Clinica...

Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1 against heavily pretreated HER2-positive breast cancer. Of 57 patients treated, 48 percent responded to the combination, with cancer control of median 8.2 months. Importantly, tucatinib acted against brain metastases stemming from HER2+ breast cancer, a major cause of mortality from the disease.

"One of the best things about this drug is that it combines well with nearly everything. It is so well tolerated that when you test tucatinib in combination with other drugs, it feels like you're just giving the other drug. It's a pill. It works. And it hardly causes side effects. It's really a doctor's dream," says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at CU Cancer Center.

.... tucatinib is being evaluated in a number of other trials and with additional partners...


Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer

https://www.practiceupdate.com/c/70229/67/13/?elsc...

  • In this phase IB study of 57 patients with metastatic or unresectable locally advanced ERBB2/HER2-positive breast cancer treated previously with trastuzumab and a taxane, the maximum tolerated dosage of tucatinib combined with ado-trastuzumab emtansine was determined to be 300 mg administered orally twice daily; the objective response rate was 48%. Median progression-free survival was 8.2 months.
  • Tucatinib in combination with ado-trastuzumab emtansine had acceptable toxicity and showed preliminary antitumor activity among heavily pretreated patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases.
"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 4, 2018 04:31AM Lumpie wrote:

Managing multiple ipsilateral breast cancer with potential new surgical options

https://www.news-medical.net/news/20180713/Managin...

A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy. Out of 198 eligible women in the trial, 184 (92.9%) successfully completed breast-conserving surgery, 134 of those with a single operation. These findings have just been published online first in Annals of Surgical Oncology.

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 4, 2018 04:41AM Lumpie wrote:

Circulating ESR1 Mutations at the End of Aromatase Inhibitor Adjuvant Treatment and After Relapse in Breast Cancer

https://www.practiceupdate.com/c/69780/67/13/?elsc...

  • In this retrospective study, plasma samples from 42 patients with metastatic breast cancer who completed at least 2 years of aromatase inhibitor treatment and relapsed were assessed for circulating ESR1 mutations. No ESR1 mutations were detectable at the end of adjuvant therapy; however, 5.4% of patients had a detectable mutation at first relapse, and 33% of patients on first-line metastatic treatment receiving aromatase inhibitor therapy had a detectable circulating mutation at time of progression compared with no patients receiving chemotherapy.
  • The authors came to the conclusion that detection of circulating ESR1 mutations at the end of aromatase inhibitor–based adjuvant therapy is not clinically useful.
"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 4, 2018 04:43AM Lumpie wrote:

Alpelisib and T-DM1 in HER2+ Metastatic Breast Cancer After Trastuzumab and Taxane Therapy

https://www.practiceupdate.com/c/69777/67/13/?elsc...

  • In this study, 17 patients with trastuzumab- and taxane-resistant HER2-positive metastatic breast cancer were treated with alpelisib and T-DM1. Maculopapular rash was the dose-limiting toxicity, and the maximum tolerated dose was alpelisib 250 mg daily. Of 14 evaluable patients, the overall response rate was 43%, whereas the overall response rate was 30% in 10 patients with prior treatment and progression on T-DM1. In evaluable patients and patients with prior T-DM1 therapy, the clinical benefit rate was 71% and 60%, respectively.
  • These findings demonstrate the tolerability and activity of alpelisib and T-DM1 in patients with trastuzumab- and taxane-resistant HER2-positive metastatic breast cancer.
"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 4, 2018 05:04AM Lumpie wrote:

Generation of HER2-Specific Antibody Immunity During Adjuvant Trastuzumab and Reduced Relapse in Resected HER2 Breast Cancer

https://www.practiceupdate.com/C/69665/56?elsca1=e...

  • This study analyzed serum anti-HER2 antibodies from a subset of patients enrolled in the NCCTG trial N9831, which includes arm A, in which trastuzumab was not used. Arms B and C received trastuzumab sequentially or concurrently to chemotherapy, respectively. The mean levels of antibodies increased in the trastuzumab arms but not in the chemotherapy-only arm. The proportion of patients who demonstrated antibodies increased by 4% in arm A and by 43% in arms B and C combined (P = .003). Cox modeling demonstrated that larger increases in antibodies were associated with longer disease-free survival in all patients (HR, 0.23; P = .04).
  • The authors suggest that the increased endogenous antibody immunity observed in patients treated with adjuvant combination trastuzumab and chemotherapy is clinically significant in view of its association with improved disease-free survival. The findings may have important implications for predicting treatment outcomes in patients treated with trastuzumab in the adjuvant setting.
"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 6, 2018 03:33PM Lumpie wrote:

Association of Transforming Growth Factor β Polymorphism C-509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer

https://www.practiceupdate.com/C/71045/56?elsca1=e...

  • This prospective cohort study evaluating 174 participants in a randomized clinical trial found grade 2 or higher breast fibrosis 3 years after radiotherapy in 13.8% of patients with the C−509T variant allele vs 3.8% of patients without the variant allele, a significant difference.
  • The C−509T variant allele may be used prospectively as a genetic marker to identify patients at elevated risk for fibrosis following radiotherapy.
"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 7, 2018 02:40AM MinusTwo wrote:

Cardiotoxicity - heart issues & BC treatment

https://lofi.medicalxpress.com/news/2018-08-priori...

2/15/11 BMX-DCIS 2SNB clear-TEs; 9/15/11-410gummies; 3/20/13 recurrance-5.5cm,mets to lymphs, Stage IIIB IDC ER/PRneg,HER2+; TCH/Perjeta/Neulasta x6; ALND 9/24/13 1/18 nodes 4.5cm; AC chemo 10/30/13 x3; herceptin again; Rads Feb2014
Log in to post a reply

Aug 8, 2018 03:02AM Lumpie wrote:

ASCO Endorses SIO Guideline for Integrative Tx in Breast Cancer

https://www.practiceupdate.com/C/71666/56?elsca1=e...

Guideline recommends therapies for reducing anxiety/stress, depression/mood disorders, nausea

After determining that the SIO guideline recommendations were clear, thorough, and based on the most relevant scientific evidence, the ASCO Expert Panel endorsed the guideline with a few added points of discussion. Key recommendations include music therapy, meditation, stress management, and yoga for reduction of anxiety/stress. For depression/mood disorders, meditation, relaxation, yoga, massage, and music therapy are recommended. To improve quality of life, meditation and yoga are recommended. For reducing chemotherapy-induced nausea and vomiting, acupressure and acupuncture are recommended. Because of a possibility of harm, acetyl-L-carnitine is not recommended to prevent chemotherapy-induced peripheral neuropathy.

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 8, 2018 04:26AM marijen wrote:

Wow! So after the cut, poison and burn of conventional western medicine, we are supposed to get over it on our own by listening to music or meditating? Or drag our beat up bodies out to yoga class or acupuncture appointments? Nevermind if some are working through all this and have husbands and children and a house to tend to. Are they kidding! That may work for some over achievers I suppose....


Log in to post a reply

Aug 8, 2018 03:23PM KPW3 wrote:

John Smith (who started an immunotherapy thread here) shared this on facebook:

An interesting commentary called "Curing Metastatic Breast Cancer".
http://ascopubs.org/doi/full/10.1200/jop.2015.008953
Here's some of the highlights.

Lines of Evidence suggesting MBC is curable.
1. Adjuvant therapy cures micrometastasis.
2. Adjuvant therapy after isolated local-regional recurrence improves survival.
3. Chemotherapy for overt metastatic disease produces long-term survivors.
4. Exceptional responders with novel agents.
5. Treatment of low-volume metastatic disease with surgery and radiation produces long-term survivors.

Suggested ways to improve outcomes:
1. Earlier detection of metastatic breast cancer through better imaging.
2. Early detection of treatable genomic lesions with ctDNA (Liquid biopsies).
3. Generate numerous exceptional responders.
4. Target genetically smart cancers with Immunotherapy approaches.

Dx 10/2014, IDC, 2cm, Stage IIB, Grade 3, 2/3 nodes, ER+/PR-, HER2- Surgery 1/27/2015 Lumpectomy Chemotherapy 3/1/2015 AC + T (Taxol) Surgery 7/21/2015 Lymph node removal: Underarm/Axillary Radiation Therapy 9/15/2015 Dx 11/29/2017, IDC, Left, Stage IV, metastasized to liver, Grade 3, ER-/PR-, HER2- Chemotherapy 6/12/2018 Halaven (eribulin) Chemotherapy Abraxane (albumin-bound or nab-paclitaxel) Hormonal Therapy Femara (letrozole), Zoladex (goserelin)
Log in to post a reply

Aug 8, 2018 03:25PM illimae wrote:

marijen,

Lol! I love how you put that, the description is very amusing but as one of the over achievers, I couldn’t agree more about the benefits of exercise. In fact, I did my 1st 5k during chemo and my 2nd a week after brain radiation, while working and taking care of the house/husband/dog.

Diagnosed at 41 Stage IV De Novo Dx 11/16/2016, IDC, Left, 5cm, Stage IV, metastasized to bone, Grade 3, 3/13 nodes, ER+/PR-, HER2+ (IHC) Chemotherapy 1/2/2017 Abraxane (albumin-bound or nab-paclitaxel) Targeted Therapy 1/2/2017 Herceptin (trastuzumab) Targeted Therapy 1/2/2017 Perjeta (pertuzumab) Surgery 6/26/2017 Lumpectomy: Left; Lymph node removal: Underarm/Axillary Radiation Therapy 8/10/2017 Breast, Lymph nodes Dx 10/5/2017, IDC, Left, Stage IV, metastasized to brain Radiation Therapy 10/20/2017 External: Brain Hormonal Therapy Tamoxifen pills (Nolvadex, Apo-Tamox, Tamofen, Tamone)
Log in to post a reply

Aug 10, 2018 03:38AM Lumpie wrote:

marijen, I laughed out loud when I saw your post! I so sympathize... exactly when am I supposed to have time for meditation...? (I sure hope they don't send the meditation police for me!) Of course, this may allow some people to get insurance coverage for acupuncture which could be helpful.

KPW3: Thanks for sharing the commentary called "Curing Metastatic Breast Cancer". I always cringe a little when I read that... I fear that any of us who are not "cured" will be deemed underachievers or that they'll decide to discontinue all our treatment since we are supposed to be cured. But real cures would certainly be reason to celebrate.

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 10, 2018 03:40AM Lumpie wrote:

Combined Digital Screening Best for Detecting Breast Cancers

https://www.practiceupdate.com/C/71789/56?elsca1=e...

The combination of digital mammography (DM) and digital breast tomosynthesis (DBT) detects 90 percent more breast cancers than digital mammography alone, according to a study published in the August issue of Radiology.

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

Aug 10, 2018 05:28AM - edited Aug 10, 2018 05:28AM by marijen

A week at a full service spa in acoastal location would surely help my stress and anxiety!

SillyHeart

Log in to post a reply

Aug 10, 2018 07:32PM Lumpie wrote:

Unmet Need for Clinician Engagement Regarding Financial Toxicity After Diagnosis of Breast Cancer

https://www.practiceupdate.com/C/71677/56?elsca1=e...

  • This survey-based study of surgeons, medical oncologists, radiation oncologists, and patients was designed to assess whether growing awareness of financial toxicity related to a cancer diagnosis and treatment has led to increased clinician engagement in the face of their patients' heavy monetary burdens and pressures. Overall, 50.9% of medical oncologists, 15.6% of surgeons, and 43.2% of radiation oncologists reported that someone often or always discusses financial burden with patients. Of women worried about finances, 72.8% reported that physicians and their staff were not helpful. Furthermore, 55.4% of women who desired to talk to providers about the impact of their disease on finances or employment did not report relevant discussion.
  • Patients report inadequate engagement with clinicians regarding management of financial toxicity, whereas many providers believe these services are made available to their patients. The authors suggest that curing the disease while bankrupting the patient is untenable.
"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

15 hours ago Lumpie wrote:

{In case you need a justification for chocolate... :) }

Moderate consumption of chocolate may reduce CVD risk

https://www.healio.com/cardiology/chd-prevention/n...

Consuming less than 100 grams of chocolate per week may help reduce cardiovascular disease risks, according to a study in the journal Heart that found 45 grams per week was the ideal amount. Researchers said the protective effect was lost when consumption was greater than 100 grams per week, or about two chocolate snack bars.

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

14 hours ago Lumpie wrote:

New strategy may lead to more accurate breast cancer diagnoses

https://www.news-medical.net/news/20180718/New-str...

A study in Molecular Oncology indicates that examining the protein and RNA in leftover materials from routine diagnostic tests for breast cancer may lead to more accurate diagnoses.

Using samples from fine needle aspiration from 25 patients with breast cancer and 33 patients with benign lesions, investigators found that such a strategy could distinguish all cancer patient samples from all benign lesions.

In addition to providing a conclusive diagnosis, the analysis may prove valuable for subtyping of breast cancer, for determining appropriate therapies for individual patients, and for monitoring the course of disease and responses to therapy, all through minimally invasive techniques.

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

14 hours ago Lumpie wrote:

Research uncovers new target for therapeutic intervention in breast cancer

https://www.news-medical.net/news/20180718/Researc...

Researches at LSU Health New Orleans School of Medicine, have shown for the first time that a tiny piece of RNA deregulates energy metabolism, an emerging hallmark of cancer. The finding identifies a new target for therapeutic intervention in breast cancer.

...miR-27b, a novel microRNA, acts as a breast cancer oncogene. It is found in abundance in breast tumors. In this study working with a line of human breast cancer cells, they demonstrated that it suppresses the production of a protein called PDHX. PDHX is involved in cell metabolism, which among other things affects cell proliferation. Its absence allows the rapid creation of new cells, promoting tumor growth and cancer progression. The team found a significant decrease in PDHX levels in breast cancer cells.

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

13 hours ago MuddlingThrough wrote:

Lumpie, thank you for all the good research links. I read a lot of them and appreciate you doing this.

Dx 1/4/2018, Stage IV, metastasized to bone/liver/other, ER+/PR+, HER2- Hormonal Therapy 3/28/2018 Femara (letrozole) Targeted Therapy 3/28/2018 Ibrance (palbociclib) Chemotherapy Taxol (paclitaxel)
Log in to post a reply

11 hours ago marijen wrote:

Scientists develop a way to deliver curcumin as an anti-cancer agent

Researchers from the university of Illinois College of Engineering have developed a way of delivering curcumin so that it can be effective as a therapeutic agent for cancer.


https://www.news-medical.net/news/20180807/Scienti...


Log in to post a reply

11 hours ago - edited 11 hours ago by marijen

Study suggests cancer to be a metabolic disorder rather than genetic disease


Excerpt:

Using mass spectrometry to measure minute quantities of sugars, amino acids and lipids in the blood of cancer patients, these scientists found metabolic signatures that clearly identified breast cancer patients with a greater than 95 percent accuracy. Breast cancer patients have changes in their metabolism that "predispose" them to the development of their disease.


https://www.news-medical.net/news/20180807/Study-s...


Log in to post a reply

9 hours ago marijen wrote:

'Dangerous Nightmare for Cancer Patients': Step Therapy

Roxanne Nelson, BSN, RN

August 09, 2018

Cancer groups have reacted negatively to an announcement from the Centers for Medicare & Medicaid Services (CMS) about allowing Medicare Advantage plans to use a "step therapy" approach to Part B drugs. The policy is part of an effort to rein in prescription drug costs.

This is a "dangerous nightmare for cancer patients," said the Community Oncology Alliance (COA), which sees it as a step toward the government's dictating what cancer treatments Medicare recipients can or cannot receive.

The American Society of Clinical Oncology (ASCO) also said it "strongly objects" to the plan, which it believes will delay access to appropriate treatments.

More at

https://www.medscape.com/viewarticle/900503


Log in to post a reply

4 hours ago - edited 4 hours ago by Lumpie

Muddling Through: Thanks for your kind words of encouragement. Glad to know that these are of some help and interest. Thanks to everyone who shares research here! (Marijen, I am particularly concerned about your last post re "step therapy." Given new FDA approved testing tools which indicate which drugs are likely to be effective.... might they require patients to use drugs they know ahead of time are not going to be effective...? Troubling. Reading and following....)

"If adventures will not befall a young lady in her own village, she must seek them abroad." "Buy the ticket, take the ride." Dx 2015, DCIS/IDC, Right, 3cm, Stage IIA, Grade 3, 0/1 nodes, ER-/PR-, HER2+ (IHC) Targeted Therapy 1/14/2016 Herceptin (trastuzumab) Chemotherapy 1/14/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel) Dx 2017, IDC, Stage IV, metastasized to liver, ER-/PR-, HER2+ Radiation Therapy Whole-breast: Breast Surgery Lumpectomy: Right Surgery Lumpectomy: Right
Log in to post a reply

4 hours ago Chemokaze wrote:

http://flip.it/sv8w_v

Experimental drug may treat 'undruggable' cancers

7/2018: Onward to Verzenio, Zometa, Faslodex, & CyberKnife to single met to L4 spine. Dx 9/1996, IDC, Left, Stage IB, Grade 3, 0/21 nodes, ER+/PR+ Dx 5/2016, IDC, Right, Stage IIIC, Grade 2, 14/21 nodes, ER+/PR+, HER2- Dx 6/2018, Stage IV, metastasized to bone
Log in to post a reply

3 hours ago marijen wrote:

Lumpie, I think there is room for appeal but who has cancer and wants to spend time on that. It’s not right. I guess we’ll find out how bad it gets. My question is why just Medicare Advantage? I hope they didn't forget to include Medicare Gap. I hope the whole darn plan is not set in atone. If Trump wants to make America Great, then Americans need to be healthy first. And if he wants the economy to grow he can’t bankrupt all the medical patients. He is working on the drug companies but this seems the wrong way to go about it I would rather they go after all the bad food choices available on market shelves.

Page 16 of 16 (479 results)